Welcome to our dedicated page for Compugen Ltd. news (Ticker: $CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen Ltd. stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Compugen Ltd.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Compugen Ltd.'s position in the market.
Compugen has published a peer-reviewed paper in Cancer Immunology Research, highlighting the unique biology of PVRIG and its therapeutic potential. PVRIG, discovered by Compugen, is expressed on stem-like T cells in dendritic cell-rich niches in tumors. The study shows that blocking PVRIG, combined with anti-TIGIT and anti-PD-1 therapies, can induce immune infiltration in non-inflamed tumors, potentially overcoming resistance to immunotherapy. Phase 1 trials of COM701, an antibody targeting PVRIG, demonstrated durable clinical responses and a favorable safety profile in typically non-responsive cancer types.
Compugen has appointed David Silberman as its new Chief Financial Officer, effective August 15, 2024, succeeding Alberto Sessa. Silberman joins from Oramed Pharmaceuticals, bringing over 15 years of finance experience, including 10 years in the healthcare and biotech industries. He has held strategic roles at Teva Pharmaceutical Industries and Grant Thornton Fahn Kanne Control Management. Compugen's CEO, Anat Cohen-Dayag, expressed confidence in Silberman's ability to drive value for shareholders and patients. Silberman is enthusiastic about joining at a time of significant growth potential, citing Compugen's innovative assets and strategic partnerships.
Compugen (Nasdaq: CGEN) will release its first quarter 2024 financial results on May 20, 2024. The company, focusing on cancer immunotherapy and computational target discovery, will host a conference call to review the results and provide a corporate update.